



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

CE
#17
[Signature]

Applicants: Kenten et al.

Patent No.: 6,660,271

Issue Date: December 9, 2003

Certificate
DEC 31 2003
of Correction

Title: UBIQUITIN FUSION-BASED VACCINE SYSTEM

CERTIFICATE OF MAILING	
I hereby certify that this correspondence is being deposited with The United States Postal Service as First Class Mail in an envelope Addressed to Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on <u>12/22/03</u>	
<u>[Signature]</u>	<u>12/22/03</u>
PIERCE ATWOOD	

REQUEST FOR CERTIFICATE OF CORRECTION

Mail Stop Issue Fee
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Applicants respectfully request that a Certificate of Correction issue under the provisions of 37 CFR 1.322. Specifically, Applicants request that the correction(s) set forth below be made to the referenced patent.

Column 17, line 54, delete "Ubicuitin" and substitute therefore ---Ubiquitin---

Column 20, line 15, delete "Ubicuitin" and substitute therefore ---Ubiquitin---

Column 21, line 19, delete "Ubiuitin" and substitute therefore ---Ubiquitin---.

Claim 5 a), column 38, line 59, before "peptide" add therefore ---GnRH---.

Claim 5 a); column 38, line 60, after the sequence, add therefore ---(SEQ ID NO: 34)---.

Claim 11, column 40, line 14, after "9," add therefore ---or---.

The Commissioner is further authorized to charge any additional fees required to process this request to Deposit Account 500282.

Respectfully submitted,



Kevin M. Farrell
Registration No. 35,505
Attorney for Applicant(s)
(603) 433-6300

Portsmouth, NH 03801

Dated: 12/18/03

P0044444.DOC

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO. : 6,660,271 *ba*

DATED : December 9, 2003

INVENTOR(S) : Kenten et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 17, line 54, delete "Ubicuitin" and substitute therefore ---Ubiquitin---.

Column 20, line 15, delete "Ubicuitin" and substitute therefore ---Ubiquitin---.

Column 21, line 19, delete "Ubiuitin" and substitute therefore ---Ubiquitin---.

~~Claim 5 a)~~ ^C Column 38, line 59, before "peptide" add therefore ---GnRH---.

~~Claim 5 a)~~ ^C Column 38, line 60, after the sequence, add therefore --- (SEQ ID NO: 34) ---.


~~Claim 11~~ ^C Column 40, line 14, after "9," add therefore ---or---.

MAILING ADDRESS OF SENDER:

Kevin M. Farrell
Pierce Atwood
One New Hampshire Avenue, Suite 350
Portsmouth, New Hampshire 03801

PATENT NO. 6,660,271

No. of additional copies

 5

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

P0045087.PDF

JAN 01 2004

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 6,660,271 B2
DATED : December 9, 2003
INVENTOR(S) : Kenten et al.

Page 1 of 1

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 17,

Line 54, delete "Ubicuitin" and substitute therefore -- Ubiquitin --.

Column 20,

Line 15, delete "Ubicuitin" and substitute therefore -- Ubiquitin --.

Column 21,

Line 19, delete "Ubiuitin" and substitute therefore -- Ubiquitin --.

Column 38,

Line 59, before "peptide" add therefore -- GnRH --.


Line 60, after the sequence, add therefore -- (SEQ ID NO: 34) --.

Column 40,

Line 14, after "9," add therefore -- or --.

Signed and Sealed this

Thirteenth Day of April, 2004

A handwritten signature in black ink, appearing to read "Jon W. Dudas". The signature is stylized with a large, looping initial "J" and a distinct "D".

JON W. DUDAS
Acting Director of the United States Patent and Trademark Office